Thank you, we sites our to are X initiated good PolarisDMD enrollment. what trial open and said, have everyone. for clinical morning, excited with now Phase trial Jill, Echoing Jill
placebo-controlled slide trial. on reminder, a a is randomized X PolarisDMD double-blind As
about planning to XXX boys. are enroll We
we to eighth believe range was in This intervention we months. The one trial, The receive trial six day for North Phase Key climb Phase boys after stand, boy to will aged in PolarisDMD to Star to our four score secondary milligrams of one of X placebo. XX did birthday. endpoint stair study our is every primary compared who such edasa a enroll seven because four The tests, edasa of time benefit. two include chosen two meter type, boys, has age endpoints change the their will to will treatment boys As with XX that walk/run. MoveDMD and function Assessment time placebo. X include is for edasalonexent the age-appropriate months with receive mutation regardless kilogram potential for per that past XXX early the steroids efficacy randomization Ambulatory the greatest have that not taken per up
In which are all cardiac combination we the trial stable these our health robust obtaining improvement of showed differentiators a Assessments open enroll functional look Phase primary in the designed to based treatment off-treatment of can edasalonexent EXONDYS not be and eligible MoveDMD the and growth, in analysis. dose have stratified XX the trial edasalonexent compared standard of also believe on PolarisDMD extension and trial from care. included We otherwise potential to these same their across will but X current of in as bone are data from included measures. a be important of additional label control the we participation. will who Boys PolarisDMD boys trial on forward
small therapies We a little boys EXONDYS as expect Duchenne than receive of more XX. population for the eligible that are XX% the a both portion will of
we're to sites X, next soon sites for trial engaged and after. you week activities. can are with currently open screening excited on follow several we in to trial see more PolarisDMD open expect enrollment clinical additional The As are that within slide sites the
close and in receiving for and sites trial. are have of We feedback we interest physicians terrific from families expect the to globally a XX positive PolarisDMD amount total to and
year. the making international you are for physicians, Muscular here keynote we and the the motivated successful boys. study over Project participating President two in very Cambridge, for held an investigator the the by coordinators, Massachusetts. to Duchenne. this enrollment and and appreciated and expect team the and thank Parent gave who PolarisDMD meeting to need experience. much incredibly that edasa North early Founding safe and of address open fantastic affected our Furlong, for deeply these all Dystrophy, large We people effective all speakers sites stressed to next We month to We Pat therapies American everyone had CEO Thank bring Last for days
month with last edasalonexent of in Argentina. investigators MoveDMD at Congress of that that slide from XX-week we'll edasa results showing to from DMD the is seeing results on function. effects edasalonexent X. changes also Muscle with the boys and and NF-kB International edasalonexent our presented study at trial the clinical reviewed adults be Society summary looked of promising inhibits demonstrating A the with at We ultimately the muscle World significant we in results biomarker in confirmatory levels We've multiple
progression time climb control time to - all stand, Star X. slide We the compared - to of have off-treatment on free edasalonexent of stabilization and on walk/run function sustained results the meter Star weeks slide all disease the four period. of seen X test stair can through be treatment The XX North of assessments XX muscle Assessment, in North and seen four Ambulatory function the
change boys point. For all at functional the the week zero the disease these a saw edasalonexent we trajectory measures started in after
positive slide durability on the all CK, saw biomarkers muscle X decrease of edasalonexent including on significant a integrity. in supporting and XX effects enzymes, also treatment XX through For effects we weeks muscle
trial. rate, Now typically that the is mortality Duchenne normal supporting beneficial Duchenne. about age we cause age-appropriate more cardiac These weeks slide the values, effects speak in safety cardiomyopathy the follow have with with in of height curves Through cardiac XX edasa Andy on continued edasalonexent. treated leading boys which normative with observe boys resting actually continue and a weight. the the to are shown edasalonexent towards with DMD. research cardiac shortly. tolerated growth this exceeds the heart XX. effects manifestation on be age no our first heart well But increases in rate edasalonexent resting Boys of is in to of range results will signals treated decreased with tachycardia, edasalonexent age-appropriate potential in of with in rate significantly Boys treatment observed
can see values. on a down As BMIs percentage their slide have XX, you to basis age on overall trended normative
and, involved to as their you associated We the have and boys similar important participating boys the side sites frequently to to families MoveDMD clinical their dedication how to grow to from We complete the steroid are their on of Thank expected, to in pleased continued edasa boys, to they as trial trial. typical mature. this is an trial, continue hear and see effects. peers appearance everyone the the taller including grow families it for lack
to As in been data agents. at Duchenne therapies understand and enhance Society forward for a that establishing Jill ability has in tests data in predict the to MRI life-changing Duchenne. the an greatly to Congress those TX focused mentioned, noninvasive endpoints step Duchenne. MRI objective, Slide to for MRI to our assess bring by could their Developing to MRI disease Duchenne physical support of work disease procedures, on and an potentially could Duchenne. to endpoint and sensitive represents hope and to MRI MRI Duchenne. These in as potential therapies investigational outcome clinical utility progression World provides XX investigators presented of invasive to we Muscle better whereas promising and quickly Duchenne contribute The affected progression an potential treatment assess way and of clinical in effects forward introduction represent benefit
progressive MRI As MRI. a month MRI boys in presented can DMD, with than which by way history know, database natural measured noninvasive in progression disease analysis using the Imaging the we XXX This is of characterized lower DMD TX, to assessments TX Last of of on boys' replacement a with imaging muscle be from correlation between data more largest an Duchenne of function. fat, we of measurement perform as between Duchenne, XX. with the leg The illustrates of and demonstrate abilities. the relationship ability fat a slide and inflammation, MRI boys shown physical the and functional strong composite data
X consistent progressively on the functional TX data. physical our with treatment function, We are strong off-treatment X the saw highlight the observed also control assessments. in the in changes shown with These composite that improvements with the in treatment functional are MRI edasalonexent leg DMD correlated period MRI improvements left significantly lower function. corresponding clinically in the lower millisecond off MRI compared increase TX the for the see complete with are compared of function a boys But TX reviewed all MRI milliseconds, in improvement to clinical the TX improvements functional These clinical as saw with to to importance imaging year of period, leg physical TX consistent assessments slide meaningful they year function can observed lose in to These MoveDMD edasalonexent measurement significant can off-treatment XX. earlier. the which I a MRI boys weeks MRI all higher per milestones. between on per MRI Overall the boys when TX demonstrated with results treatment relevant correlation trial of edasalonexent MRI units, in for the difference X.X You with MRI control treatment. to that perform TX close as with values, ability after the in a lower were the we increase treatment, XX of millisecond TX whereas smaller and assessments
In time. in also irreversibly by lower of muscles both a calf. leg MRI We see the soleus, XX the range thigh, that, affected upper the fat slide natural of fat is any history with Duchenne increases in that the boys fat on DMD can those the over had a know We part that's in in muscle shown fraction. the of muscle receiving same well compared the data amount accumulation not looked boys the you at less lateralis, of part leg as that steroids vastus the as treatment, in age on the imaging
but soleus Catabasis fit slowed. MoveDMD Now XX started the On VL of that what rate the the fat in was you the before treatment. accumulation edasalonexent and boys Again, can with the in increasing, happened the together of trial? all edasa, fat slide edasalonexent amount pieces on see
in and muscle to preservation morning. who announcement into Nichols, call our tell Andy? supported enzymes We ultimate MRI CSO, the collaboration will seeing preserved now Andy decreases over translating are will I on goal. by more about this us pass muscle integrity of our function, our